Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide’s antiproliferative effect

Journal of Neuro-Oncology

Volumn 122, Issue 1, 2015, Pages 21-33

  Karpel Massler, Georg ^a   Kast, Richard Eric ^b   Westhoff, Mike Andrew ^a   Dwucet, Annika ^a   Welscher, Nathalie ^a   Nonnenmacher, Lisa ^a   Hlavac, Michal ^a   Siegelin, Markus David ^c   Wirtz, Christian Rainer ^a   Debatin, Klaus Michael ^a   Halatsch, Marc Eric ^a  

^a UNIVERSITY OF ULM   (Germany)

^b IIAIGC Headquarters   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

Combination therapy; Glioblastoma; Olanzapine; Repurposing

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; OLANZAPINE; TEMOZOLOMIDE; ALKYLATING AGENT; BENZODIAZEPINE DERIVATIVE; DACARBAZINE; NEUROLEPTIC AGENT; PHOSPHOPROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONCENTRATION RESPONSE; CYTOSTASIS; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; IC50; NEURAL STEM CELL; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CELL ADHESION; CELL MOTION; DRUG EFFECTS; METABOLISM; PATHOLOGY; PROTEIN MICROARRAY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTIPSYCHOTIC AGENTS; APOPTOSIS; BENZODIAZEPINES; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DACARBAZINE; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; PHOSPHOPROTEINS; PROTEIN ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

EID: 84925511559     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1688-7     Document Type: Article

References (39)

1. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 15(Suppl 2):ii1–ii56
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
3. Kast RE, Karpel-Massler G, Halatsch ME (2011) Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin? Br J Pharmacol 164(5):1393–1396
4. Zhang WB, Wang Z, Shu F, Jin YH, Liu HY, Wang QJ, Yang Y (2010) Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem 285(52):40461–40471
5. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007) From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 104(9):3456–3459
6. Buckley PF (2005) Olanzapine: a critical review of recent literature. Expert Opin Pharmacother 6(12):2077–2089
7. Frye MA (2011) Clinical practice. Bipolar disorder—a focus on depression. N Engl J Med 364(1):51–59
8. Dipple HC (1999) The use of olanzapine for movement disorder in Huntington’s disease: a first case report. J Neurol Neurosurg Psychiatry 67(1):123–124
9. Grove VE Jr, Quintanilla J, DeVaney GT (2000) Improvement of Huntington’s disease with olanzapine and valproate. N Engl J Med 343(13):973–974
10. Awad AG, Voruganti LN (2004) Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18(13):877–893
11. Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Fleischhacker WW (2001) Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 158(10):1719–1722
12. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155(7):921–928
13. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14(2):87–96
14. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7(3):317–321
15. ZYPREXA: EPAR-product information. http://www.emaeuropaeu/ema/indexjsp?curl=pages/medicines/human/medicines/000115/human_med_001189jsp&murl=menus/medicines/medicinesjsp&mid=WC0b01ac058001d125. (Last Accessed 17 Dec 2013)
16. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, Swanson SP, Hamman MA, Wrighton SA (1996) Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 276(2):658–666
17. Kast RE, Foley KF (2007) Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl) 16(4):351–354
18. Khojainova N, Santiago-Palma J, Kornick C, Breitbart W, Gonzales GR (2002) Olanzapine in the management of cancer pain. J Pain Symptom Manage 23(4):346–350
19. Navari RM (2014) Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol 722:180–186
20. Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21(6):1655–1663
21. Prommer E (2013) Olanzapine: palliative medicine update. Am J Hosp Palliat Care 30(1):75–82
22. Westhoff MA, Zhou S, Nonnenmacher L, Karpel-Massler G, Jennewein C, Schneider M, Halatsch ME, Carragher NO, Baumann B, Krause A, Simmet T, Bachem MG, Wirtz CR, Debatin KM (2013) Inhibition of NF-κB signaling ablates the invasive phenotype of glioblastoma. Mol Cancer Res 11(12):1611–1623
23. Wlodkowic D, Telford W, Skommer J, Darzynkiewicz Z (2011) Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol 103:55–98
24. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suvà ML, Regev A, Bernstein BE (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396–1401
25. Liang J, Mills GB (2013) AMPK: a contextual oncogene or tumor suppressor? Cancer Res 73(10):2929–2935
26. Jeon S-M, Chandel NS, Hay N (2012) AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485(7400):661–665
27. Ferno J, Skrede J, Vik-Mo AO, Havik B, Steen VM (2006) Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci 7:69–80
28. Krzystanek M, Krzystanek E, Trzeciak HI, Malecki A, Krupka-Matuszczyk I, Janas-Kozik M, Rybakowski JK (2013) Effects of olanzapine and paroxetine on phospholipase D activity in the rat brain. Pharmacol Rep 65:724–729
29. Exton JH (1999) Regulation of phospholipase D. Biochim Biophys Acta 1439:121–133
30. Klein J (2005) Functions and pathophysiological roles of phospholipase D in the brain. J Neurochem 94:1473–1487
31. Foster DA, Xu L (2003) Phospholipase D in cell proliferation and cancer. Mol Cancer Res 1:789–800
32. Min DS, Kwon TK, Park W-S, Chang J-S, Park S-K, Ahn B-H, Ryoo ZY, Lee YH, Lee YS, Rhie D-J, Yoon S-H, Hahn SJ, Kim M-S, Jo Y-H (2001) Neoplastic transformation and tumorigenesis associated with expression of phospholipase D isozymes in cultured murine fibroblasts. Carcinogenesis 22:1641–1647
33. Park MH, Ahn BH, Hong YK, Min DS (2009) Overexpression of phospholipase D enhances matrix metalloproteinase-2 expression and glioma cell invasion via protein kinase C and protein kinase A/NF-kappaB/Sp1-mediated signaling pathways. Carcinogenesis 30:356–365
34. Bruntz RC, Taylor HE, Lindsley CW, Brown HA (2013) Phospholipase D2 mediates survival signaling through direct regulation of Akt in glioblastoma cells. J Biol Chem 289(2):600–616
35. Kim NR, Park SW, Lee JG, Kim YH (2008) Protective effects of olanzapine and haloperidol on serum withdrawal-induced apoptosis in SH-SY5Y cells. Prog Neuropsychopharmacol Biol Psychiatry 32:633–642
36. Wakade CG, Mahadik SP, Waller JL, Chiu F-C (2002) Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 69:72–79
37. Wilcock C, Bailey CJ (1994) Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24:49–57
38. Kornhuber J, Schultz A, Wiltfang J, Meineke I, Gleiter CH, Zöchling R, Boissl K-W, Leblhuber F, Riederer P (1999) Persistence of haloperidol in human brain tissue. Am J Psychiatry 156:885–890
39. Kast RE, Bookvar JA, Brüning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magné N, Marosi C, McDonald K, Munoz M, Paranjpe A, Pourgholami MH, Sardi I, Sella A, Srivenugopal KS, Tuccori M, Wang W, Wirtz CR, Halatsch M-E (2013) A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurpused drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget 4:502–530